共被期刊论文引用了2次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Recent advances in multidisciplinary management of hepatocellular carcinoma显示文摘The incidence of hepatocellular carcinoma(HCC) is increasing, and it is currently the second leading cause of cancer-related death worldwide. Potentially curative treatment options for HCC include resection, transplantation, and percutaneous ablation, whereas palliative treatments include trans-arterial chemoembolization(TACE), radioembolization, and systemic treatments. Due to the diversity of available treatment options and patients' presentations, a multidisciplinaryteam should decide clinical management of HCC, according to tumor characteristics and stage of liver disease. Potentially curative treatments are suitable for very-early- and early-stage HCC. However, the vast majority of HCC patients are diagnosed in later stages, where the tumor characteristics or progress of liver disease prevent curative interventions. For patients with intermediate-stage HCC, TACE and radioembolization improve survival and are being evaluated in addition to potentially curative therapies or with systemic targeted therapy. There is currently no effective systemic chemotherapy, immunologic, or hormonal therapy for HCC, and sorafenib is the only approved moleculartargeted treatment for advanced HCC. Other targeted agents are under investigation; trials comparing new agents in combination with sorafenib are ongoing. Combinations of systemic targeted therapies with local treatments are being evaluated for further improvements in HCC patient outcomes. This article provides an updated and comprehensive overview of the current standards and trends in the treatment of HCC. | Asmaa I Gomaa Imam Waked | 2015 | World Journal of Hepatology2015，7，4： | 15 |
| 2 | 影响肝移植治疗肝细胞癌预后的相关因素分析显示文摘目的探讨影响肝移植治疗肝细胞癌(HCC)预后的相关因素。方法回顾性分析2004年8月至2011年2月问147例HCC患者接受肝移植治疗的临床资料。单因素分析共纳入14个指标:受者性别、年龄、血型、术前肝功能分级、终末期肝病模型评分、甲胎蛋白(AFP)水平、肿瘤数目、肝脏被肿瘤取代率、是否侵犯左右叶、累计肿瘤直径、是否侵犯肝包膜、大血管受侵犯、微血管受侵犯(MVI)以及HCC组织学分级。将差异有统计学意义的指标纳入Cox风险比例模型行多因素分析,筛选出独立危险因素。结果143例受者获得完整随访,随访时间6-84个月,术后1、3年总体存活率分别为75.2%和54.7%,无瘤存活率分别为70%和59%。单因素分析显示,受者年龄、AFP水平、肿瘤数目、累计肿瘤直径、肝脏被肿瘤取代率、侵犯左右叶、侵犯肝包膜、大血管受侵犯、MVI等指标的差异有统计学意义(P〈0.05);经多因素分析,MVI、大血管受侵犯和AFP≥400“g/L是影响HCC患者肝移植术后存活率的独立危险因素。结论MVI、大血管受侵犯、AFP是影响HCC肝移植术后存活率的主要危险因素,肝移植术前对其进行适当干预,术中严格按照无瘤技术操作,可明显改善预后。 | 谭永法 阚和平 谭凯 付文广 陈剑尉 王恺 周杰 | 2012 | 中华器官移植杂志2012，33，6： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员